Singapore markets close in 6 hours 9 minutes
Straits Times Index
3,355.34 +16.77 (+0.50%) Nikkei
39,780.58 +149.52 (+0.38%) Hang Seng
17,900.72 +182.11 (+1.03%) FTSE 100
8,166.76 +2.64 (+0.03%) Bitcoin USD
62,930.63 -363.05 (-0.57%) CMC Crypto 200
1,345.07 +43.00 (+3.30%)
PCVX Jul 2024 45.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:34AM EDT. Market open.
Loading interactive chart…
- Simply Wall St.
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
- GlobeNewswire
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
© 2024 Yahoo. All rights reserved.